Bio-Rad Laboratories (FRA:BUWA) Ending Cash Position: €450 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BUWA Bio-Rad Laboratories Inc FRA:BUWA
71 GF Score
Price €307.20
GF Value €276.59
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bio-Rad Laboratories Ending Cash Position?

Bio-Rad Laboratories FRA:BUWA -1.66% 71 Ending Cash Position is €450 Mil as of Jun. 2026. GuruFocus rates FRA:BUWA with a GF Score™ of 71/100 and a GF Value™ of €276.59 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Bio-Rad Laboratories's Ending Cash Position for the quarter that ended in Jun. 2026 was €450 Mil.

Bio-Rad Laboratories's quarterly Ending Cash Position declined from Dec. 2025 (€454 Mil) to Mar. 2026 (€440 Mil) but then increased from Mar. 2026 (€440 Mil) to Jun. 2026 (€450 Mil).

Bio-Rad Laboratories's annual Ending Cash Position increased from Dec. 2023 (€371 Mil) to Dec. 2024 (€468 Mil) but then declined from Dec. 2024 (€468 Mil) to Dec. 2025 (€454 Mil).

Bio-Rad Laboratories Ending Cash Position Related Terms

Bio-Rad Laboratories Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Bio-Rad Laboratories's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Rad Laboratories Ending Cash Position Chart

Bio-Rad Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 416.95 410.17 370.84 467.76 454.50

Bio-Rad Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 322.26 339.27 454.50 440.29 450.32
FRA:BUWA
71GF Score
Bio-Rad Laboratories Inc FRA:BUWA
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio-Rad Laboratories Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Bio-Rad Laboratories's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=418.29+36.209
=454

Bio-Rad Laboratories's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=441.812+8.506
=450

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €450 Mil mean?
Bio-Rad Laboratories (FRA:BUWA) has a Ending Cash Position of €450 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Bio-Rad Laboratories and its competitors.
Is Bio-Rad Laboratories' Ending Cash Position too high?
Bio-Rad Laboratories' current Ending Cash Position is €450 Mil. Overall, Bio-Rad Laboratories has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' Ending Cash Position compare to GKOS and BRKR?
Bio-Rad Laboratories' Ending Cash Position of €450 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Bio-Rad Laboratories and its competitors. Bio-Rad Laboratories's current Ending Cash Position is €450 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Modestly Overvalued. The stock's GF Value™ is €276.59, compared to a current price of €307.20 — trading 11.1% above its estimated fair value. The current Ending Cash Position is €450 Mil. Bio-Rad Laboratories' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current Ending Cash Position is €450 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be overvalued. The current stock price of €307.20 is trading 11.1% above its estimated GF Value™ of €276.59. GuruFocus considers Bio-Rad Laboratories to be Modestly Overvalued.

Key valuation signals for FRA:BUWA:

  • Ending Cash Position: €450 Mil
  • GF Value™: €276.59 vs. price of €307.20 (11.1% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bio-Rad Laboratories Business Description

Address 1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
71GF Score

Get the complete analysis for FRA:BUWA

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€307.20
Price
€276.59
GF Value